Introduction/Background

Adjuvant capecitabine monotherapy is an option for colon and upper rectum adenocarcinoma patients, providing they have stage II disease with an intermediate risk of recurrence, or stage III but they are above 70’s or they have comorbidities. We wanted to examine whether the number of chemotherapy cycles and the relative dose intensity (RDI) of capecitabine monotherapy in the adjuvant setting are affecting disease recurrence.

Patients and Methods

We included patients with completely resected stage II and III colon and upper rectum cancer who received adjuvant capecitabine monotherapy, from 2003 until May 2020. Patients with early relapse, i.e. during chemotherapy or within 6 months after the completion of adjuvant chemotherapy, and those with rectal cancer who received radiotherapy were excluded. Patients were divided into 3 groups based on the number of chemotherapy cycles received and the RDI. Group A included patients with ≤4 cycles of chemotherapy, group B patients with >4 cycles of chemotherapy and RDI ≤80%, and group C patients with >4 cycles of chemotherapy and RDI >80%. Study’s endpoint, was recurrence free survival (RFS).

Results

Two hundred twenty six patients with stage II and III disease (164 and 62 respectively) were included. Sixteen, 166 and 44 were included in groups A, B and C respectively. After a median follow-up of 41 months, 21 patients (9,3%) had relapsed. Patients belonging to group C were found to have a trend for lower relapse rate compared to patients belonging to group A or group B.

Conclusion

Number of adjuvant capecitabine cycles and RDI might play a role in RFS in patients with stage II and III colon and upper rectum adenocarcinoma.

中文翻译：

---

接受卡培他滨单药辅助治疗的结肠和上直肠腺癌 II 期和 III 期患者的疾病复发率：化疗周期数和药物相对剂量强度是否起作用？

简介/背景

辅助卡培他滨单药治疗是结肠和上直肠腺癌患者的一种选择，前提是他们患有具有中等复发风险的 II 期疾病，或 III 期但年龄超过 70 岁或有合并症。我们想要检查化疗周期数和辅助治疗中卡培他滨单药治疗的相对剂量强度 (RDI) 是否影响疾病复发。

患者和方法

我们纳入了 2003 年至 2020 年 5 月期间接受卡培他滨单药辅助治疗的完全切除的 II 期和 III 期结肠癌和上直肠癌患者。早期复发患者，即化疗期间或辅助化疗完成后 6 个月内，以及直肠癌患者接受放射治疗的癌症被排除在外。根据接受的化疗周期数和 RDI，将患者分为 3 组。A组包括≤4个周期化疗的患者，B组为>4个周期化疗且RDI≤80%的患者，C组为>4个周期化疗且RDI>80%的患者。研究的终点是无复发生存期（RFS）。

结果

其中包括 226 名 II 期和 III 期疾病患者（分别为 164 名和 62 名）。A、B、C 组分别包括 16 名、166 名和 44 名。中位随访 41 个月后，21 名患者 (9.3%) 复发。研究发现，与 A 组或 B 组患者相比，C 组患者的复发率有较低的趋势。

结论

辅助卡培他滨周期数和 RDI 可能在 II 期和 III 期结肠癌和直肠上段腺癌患者的 RFS 中发挥作用。